Search clinical trials for: SHR1459

Total 19 results

Reistone Biopharma Company Limited

Active, not recruiting

Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Reistone Biopharma Company Limited

Completed

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

Neuromyelitis Optica Spectrum Disorders

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Mature B Cell Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Biliary Tract Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Completed

A Phase I Study of SHR1459 in Healthy Subjects

Health, Subjective

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

B-cell Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

China
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China

Search clinical trials for: SHR1459

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations